Severe community-acquired pneumonia: Optimal management

Current Opinion in Infectious Diseases

Volumn 30, Issue 2, 2017, Pages 240-247

  Leoni, Davide ^a,b   Rello, Jordi ^b,c,d  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b Clinical Research and Innovation in Pneumonia and Sepsis (CRIPS)   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Biomarkers; Genome wide assessment study; Microbiomics; Mortality; Rapid molecular testing; Viral pneumonia

Indexed keywords

BIOLOGICAL MARKER; ANTIINFECTIVE AGENT;

COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DISEASE SEVERITY ASSESSMENT; HUMAN; MORTALITY; PATHOGENESIS; PERSONALIZED MEDICINE; PREDICTION; REVIEW; TREATMENT OUTCOME; BACTERIAL PNEUMONIA; BLOOD; COMMUNITY ACQUIRED INFECTION; MICROBIOLOGY; VIRUS PNEUMONIA;

ANTI-BACTERIAL AGENTS; BIOMARKERS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL;

EID: 85008686784     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000349     Document Type: Review

References (27)

1. Ostermann H, Garau J, Medina J, et al. Resource use by patients hospitalized with community-Acquired pneumonia in Europe: Analysis of the REACH study. BMC Pulm Med 2014; 14: 36.
2. Cavallazzi R, Wiemken T, Arnold FW, et al. Outcomes in patients with community-Acquired pneumonia admitted to the intensive care unit. Respir Med 2015; 109: 743-750.
3. Simonetti AF, Garcia-Vidal C, Viasus D, et al. Declining mortality among hospitalized patients with community-Acquired pneumonia. Clin Microbiol Infect 2016; 22: 567.e1-e7.
4. Vallés J, Diaz E, Martín-Loeches I, et al. Evolution over a 15-year period of the clinical characteristics and outcomes of critically ill patients with severe community-Acquired pneumonia. Med Intensiva 2016; 40: 238-245.
5. Gattarello S, Lagunes L, Vidaur L, et al. Improvement of antibiotic therapy and ICU survival in severe nonpneumococcal community-Acquired pneumonia: A matched case-control study. Crit Care 2015; 19: 335.
6. Gattarello S, Borgatta B, Solé-Violán J, et al. Decrease in mortality in severe community-Acquired pneumococcal pneumonia: Impact of improving antibiotic strategies (2000-2013). Chest 2014; 146: 22-31.
7. Garin N, Felix G, Chuard C, et al. Predictors and implications of early clinical stability in patients hospitalized for moderately severe community-Acquired pneumonia. PLoS One 2016; 11: E0157350.
8. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801-810.
9. Montull B, Menéndez R, Torres A, et al. Predictors of severe sepsis among patients hospitalized for community-Acquired pneumonia. PLoS One 2016; 11: E0145929.
10. Zhuang Y, Li W, Wang H, et al. Predicting the outcomes of subjects with severe community-Acquired pneumonia using monocytes human leukocyte antigen-DR. Respir Care 2015; 60: 1635-1642.
11. Klouche K, Cristol JP, Devin J, et al. Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and community-Acquired pneumonia in ICU patients. Ann Intensive Care 2016; 6: 59.
12. Pereira JM, Azevedo A, Basílio C, et al. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe communityacquired pneumonia? Rev Port Pneumol (2006) 2016; 22: 308-314.
13. Neugebauer S, Giamarellos-Bourboulis EJ, Pelekanou A, et al. Metabolite profiles in sepsis: Developing prognostic tools based on the type of infection. Crit Care Med 2016; 44: 1649-1662.
14. To KK, Lee KC, Wong SS, et al. Lipid metabolites as potential diagnostic and prognostic biomarkers for acute community acquired pneumonia. Diagn Microbiol Infect Dis 2016; 85: 249-254.
15. Liu J, Wu X, Lu F, et al. Low T3 syndrome is a strong predictor of poor outcomes in patients with community-Acquired pneumonia. Sci Rep 2016; 6: 22271.
16. Rautanen A, Mills TC, Gordon AC, et al. Genome-wide association study of survival from sepsis due to pneumonia: An observational cohort study. Lancet Respir Med 2015; 3: 53-60.
17. Pettigrew MM, Gent JF, Kong Y, et al. Association of sputum microbiota profiles with severity of community-Acquired pneumonia in children. BMC Infect Dis 2016; 16: 317.
18. Jain S, Self WH, Wunderink RG, et al. Community-Acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373: 415-427.
19. Tan D, Zhu H, Fu Y, et al. Severe community-Acquired pneumonia caused by human adenovirus in immunocompetent adults: A multicenter case series. PLoS One 2016; 11: E0151199.
20. Farida H, Gasem MH, Suryanto A, et al. Viruses and Gram-negative bacilli dominate the etiology of community-Acquired pneumonia in Indonesia, a cohort study. Int J Infect Dis 2015; 38: 101-107.
21. Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive molecular testing for respiratory pathogens in community-Acquired pneumonia. Clin Infect Dis 2016; 62: 817-823.
22. Yoshii Y, Shimizu K, Morozumi M, et al. Identification of pathogens by comprehensive real-Time PCR versus conventional methods in communityacquired pneumonia in Japanese adults. Infect Dis (Lond) 2016; 22: 1-7.
23. Gelfer G, Leggett J, Myers J, et al. The clinical impact of the detection of potential etiologic pathogens of community-Acquired pneumonia. Diagn Microbiol Infect Dis 2015; 83: 400-406.
24. Messaoudi M, Milenkov M, Albrich WC, et al. The relevance of a novel quantitative assay to detect up to 40 major Streptococcus pneumoniae serotypes directly in clinical nasopharyngeal and blood specimens. PLoS One 2016; 11: E0151428.
25. Sweeney TE, Wong HR, Khatri P. Robust classification of bacterial and viral infections via integrated host gene expression diagnostics. Sci Transl Med 2016; 8: 346ra91.
26. Calfee CS Opening the Debate on the New Sepsis Definition. Precision medicine: An opportunity to improve outcomes of patients with sepsis. Am J Respir Crit Care Med 2016; 194: 137-139.
27. Rello J, Perez A. Precision medicine for the treatment of severe pneumonia in intensive care. Expert Rev Respir Med 2016; 10: 297-316.